Stock Ratings / Health Care / TRLV / earnings

CRON (52) RGC (38) DFTX (52) TLRY (32) ⌘ Pro Terminal →

Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) Next Earnings Date & Expected ±12.5% Move

$10.60 -0.19% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.58

Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $2.04B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.58 (-0.22%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 19.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TRLV)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (58/100 Composite)

🔍 WHY TRLV SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+16/20 pts (28% of score)

FRED Regime × Technicals: 69% of 52W Range • RSI-14 at 43.3 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 19.4% FCF Margin ($228.6M FCF) & 60.2% Gross Margin

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk8/20 pts (-12 pt drag)

Balance-sheet & 10-K footnote risk deducts 12 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$10.67-6.2% Next Q

Q2 (-2Q)

Grade C+$10.01+4.1% Next Q

Q3 (-1Q)

Grade C$10.42+1.7% Next Q

Current

Grade D+$10.60+0% Hist 90D α

Trajectory: B- (66) → D+ (58)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the TRLV Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 58/100 (D+) score, TRLV faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 57.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($11.19) or 200D SMA ($8.82) invalidates the momentum regime and cuts Target Base ($10.60) toward Bear Floor ($8.27).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TRLV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TRLV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 58%NO 42%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.32 Expected Swing

MODEL EARNINGS SETUP GAUGE

TRLV Quantitative Pre-Earnings Setup: 58/100

Trailing EPS: $4.25 • YoY Revenue Growth: -0.4%

Model Bullish Setup (58/100)Model Risk Weight (42/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$1.18B	-$116.4M	$228.6M	60.2%
FY 2024	2024-12-31	$1.19B	-$155.1M	$148.9M	60.3%
FY 2023	2023-12-31	$1.13B	-$526.8M	$201.8M	60.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TRLV)

✓Walkthrough of TRLV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TRLV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.72%▲ ASCENDING CHANNEL

2026-10-30O $10.46H $10.60L $9.90C $10.60VOL 1.41M

RES: $14.83SUP: $8.65SMA50: $11.19SMA200: $8.82

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TRLV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TRLV Butterfly Map → + Track TRLV →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

3.1%/yr Implied 5Y Growth

vs. -0.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TRLV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TRLV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TRLV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TRLV)

Health Care Rank #225 of 1016 ⚔️ CRON vs TRLV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TRLV vs. CRON, RGC, DFTX, TLRY)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) ranks #225 by composite RQD confidence (58/100, grade D+) and #258 by equity capitalization ($2.04B). Within this direct 5-issuer industry benchmark cohort, TRLV leads on earnings valuation at N/A trailing P/E, while TRLV leads on capital efficiency and profitability with 12.8% ROIC and 60.2% gross margin. TRLV currently leads its immediate peer cohort in composite quantitative strength at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TRLV ACTIVE Trulieve Cannabis Corp. Subordinate Voting Shares	D+	58/100	—	60.2%	12.8%	-0.19%	$2.04B	Benchmark Subject
CRON Cronos Group Inc. Common Share	D+	52/100	—	42.8%	-4.5%	+0.30%	$1.24B	/cron-vs-trlv →
RGC Regencell Bioscience Holdings Limited	D-	38/100	—	—	—	-5.64%	$3.40B	/rgc-vs-trlv →
DFTX Definium Therapeutics Inc.	D+	52/100	—	—	-32.2%	-0.37%	$5.10B	/dftx-vs-trlv →
TLRY Tilray Brands Inc.	E	32/100	—	28.4%	-3.9%	-1.86%	$390.2M	/tlry-vs-trlv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001754195

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) reported GAAP revenue of $1.18B (-0.4% vs. FY2024 revenue of $1.19B , and +4.6% cumulative change since FY2023) , GAAP net income of -$116.4M, operating cash flow of $272.8M, and free cash flow of $228.6M (+53.6% YoY). On the balance sheet, TRLV closed FY2025 with $2.70B in total assets against $0 in total debt (Altman Z-Score: 1.12, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.18B	-$116.4M	$272.8M	$228.6M	$2.70B	—
FY2024 (FY)	2024-12-31	$1.19B	-$155.1M	$271.5M	$148.9M	$2.87B	—
FY2023 (FY)	2023-12-31	$1.13B	-$526.8M	$201.8M	$201.8M	—	—

3. TRLV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TRLV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Trulieve Cannabis Corp. Subordinate Voting Shares (NYSE: TRLV) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $10.60 (-0.19% 1D, market cap $2.04B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, TRLV ranks #225 in composite RQD confidence.

How does TRLV compare to CRON and RGC in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), TRLV carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of 60.2%, and ROIC of 12.8%. By comparison, CRON (Cronos Group Inc. Common Share) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -4.5%, cap $1.24B) and RGC (Regencell Bioscience Holdings Limited) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.40B). Among the 5-stock peer group, TRLV leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TRLV?

Per TRLV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001754195), Trulieve Cannabis Corp. Subordinate Voting Shares generated $1.18B in revenue (-0.4% YoY), -$116.4M in net income, and $228.6M in free cash flow against $2.70B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TRLV trading relative to its 50-day, 200-day, and 52-week technical levels?

TRLV last traded at $10.60 (-0.19% on volume of 1,034,372 shares), positioning the stock -5.27% below its 50-day simple moving average ($11.19) and +20.18% above its 200-day simple moving average ($8.82). Across its 52-week range of $4.62 to $13.28, TRLV sits at the 69.1% percentile with a 14-day RSI of 43.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.28 to $11.92).

TRLV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is TRLV's next earnings date?

Based on SEC filing cadence, Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is TRLV stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for TRLV, spanning a range between $9.28 and $11.92.

Direct Sub-Reports: TRLV RQD Cockpit TRLV 12M Forecast TRLV Earnings & Move TRLV Dividends & DRIP TRLV Insiders & 13F TRLV Whale Options TRLV Profit Sankey TRLV News & Why